Clemondo Group (CLEM) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
10 Nov, 2026Executive summary
Q3 2026 net sales rose 3% YoY to SEK 67.5m, marking the ninth consecutive quarter of sales growth; the quarter is seasonally the weakest.
Higher input costs linked to the situation in the Strait of Hormuz outweighed sales growth, compressing gross margin and reducing earnings.
Focus remains on pricing, efficiency and cost control while continuing strategic initiatives and pursuing long-term profitable growth.
Financial highlights
Q3 revenue SEK 67.5m vs SEK 65.3m; EBITDA SEK 2.5m vs SEK 5.1m; EBIT -SEK 1.5m vs SEK 1.4m.
Q3 net loss SEK 2.0m vs net income SEK 0.7m; EPS -SEK 0.15 vs SEK 0.05.
9M revenue SEK 226.2m vs SEK 213.4m; EBITDA SEK 13.4m vs SEK 17.3m; net loss SEK 0.7m vs net income SEK 3.9m.
Q3 gross margin fell to 33.5% from 39.6%; gross profit declined SEK 3.0m YoY despite higher sales.
Other and personnel costs together declined SEK 0.4m YoY; depreciation and amortization was SEK 4.0m vs SEK 3.7m.
Outlook and guidance
Financial targets: annual growth of at least 12%, half organic; EBITDA margin of at least 10% over a business cycle; equity ratio of at least 30%.
Near-term priorities are to improve profitability through price adjustments and efficiency while advancing strategic initiatives and improving capacity utilization.
Longer term, management sees significant opportunities for profitable growth across its market areas.
Latest events from Clemondo Group
- Q2 2026 saw 9% sales growth, margin improvement, and strong Vehicle and Medical Care performance.CLEM
Q2 2026 - Sales up 5% with strong Medical Care growth, but margins fell due to higher investment costs.CLEM
Q1 2026 - Q4 2025 saw 11% sales growth, margin pressure from investments, and strong Medical Care gains.CLEM
Q4 2025 - Q3 2025 saw 13% sales growth and strong segment performance, but lower margins due to investments.CLEM
Q3 2025 - Net sales rose 9% year-over-year, with strong growth in Medical Care and Industrial segments.CLEM
Q2 2025 - Q3 2024 saw stable earnings, strong equity, and growth in Hygien and Industri amid a weak market.CLEM
Q3 2024 - Sales declined but gross margin and financial position improved, with growth in Hygiene and Industry.CLEM
Q2 2024 - Q1 2025 saw 12% sales growth, margin expansion, and Medical Care emerge as a key growth driver.CLEM
Q1 2025 - Hygiene and Industry growth offset Vehicle weakness, with strong equity and new contracts for 2025.CLEM
Q4 2024